The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: A molecular perspective

Clinical and Translational Oncology

Volumn 9, Issue 12, 2007, Pages 752-759

  Urruticoechea, A ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Aromatase inhibitors; Breast cancer; Cross talk; Endocrine treatment; Resistance

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; ESTROGEN; FULVESTRANT; GEFITINIB; LETROZOLE; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR THERAPY; PREDICTION; REVIEW; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG RESISTANCE; FEMALE; NEOPLASM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 39149098513     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0136-y     Document Type: Review

References (59)

1. Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987-4991
2. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47-61
3. Adeyinka A, Emberley E, Niu Y et al (2002) Analysis of gene expression in ductal carcinoma in situ of the breast. Clin Cancer Res 8:3788-3795
4. Verlinden I, Janssens J, Raus J, Michiels L (2004) Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast. Mol Carcinog 41:197-206
5. Shoker BS, Jarvis C, Clarke RB et al (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811-1815
6. Li CI, Daling JR, Malone KE (2003) Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28-34
7. McGuire JL, Bariso CD, Fuller BS et al (1972) Preliminary isolation of an estrogen specific binding macromolecule from the human uterus. J Clin Endocrinol Metab 34:243-246
8. Shang Y, Hu X, DiRenzo J et al (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
9. Osborne CK, Schiff R, Fuqua SA, Shou J (2001) Estrogen receptor: Current understanding of its activation and modulation. Clin Cancer Res 7[12 Suppl]:4338s-4342s; discussion 4411s-4412s
10. McKenna NJ, Lanz RB, O'Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344
11. Carroll JS, Meyer CA, Song J et al (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297
12. Kushner PJ, Agard DA, Greene GL et al (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317
13. McGuire JL et al (1972) Preliminary isolation of an estrogen specific binding macromolecule from the human uterus. J Clin Endocrinol Metab 34:243-246
14. Sun M, Paciga JE, Feldman RI et al (2001) Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61:5985-5991
15. Kahlert S, Nuedling S, van Eickels M et al (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275:18447-18453
16. Filardo EJ, Quinn JA, Bland KI, Frackelton AR (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660
17. Bunone G, Briand PA, Miksicek RJ, Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
18. Font de Mora J, Brown M (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041-5047
19. Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 276:9817-9824
20. Cicatiello L, Scafoglio C, Altucci L et al (2004) A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 32:719-775
21. Frasor J, Danes JM, Komm B et al (2003) Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574
22. Inoue A, Yoshida N, Omoto Y et al (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29:175-192
23. McKay LI, Cidlowski JA (1999) Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435-459
24. Speir E, Yu Z-X, Takeda K et al (2000) Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ Res 87:1006-1011
25. Beatson G (1896) On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104-107
26. (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev (1):CD000486
27. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
28. Rabaglio M, Aebi S, Castiglione-Gertsch M (2007) Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8:940-949
29. Mackay A, Urruticoechea A, Dixon JM et al (2007) Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 9:R37
30. Cleator S, Tsimelzon A, Ashworth A et al (2006) Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95:229-233
31. Cleator SJ, Powles TJ, Dexter T et al (2006) The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 8:R32
32. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
33. Berry DA, Muss HB, Thor AD et al (2000) HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 18:3471-3479
34. Ciocca DR, Elledge R (2000) Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13:1-10
35. Elledge RM, Green S, Ciocca D et al (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12
36. Elledge RM, Green S, Howes L et al (1997) bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol 15:1916-1922
37. Kenny FS, Hui R, Musgrove EA et al (1999) Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5:2069-2076
38. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816
39. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
40. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
41. Bennink RJ et al (2004) In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 45:1-7
42. Van Den Bossche B, Van Belle S, De Winter F et al (2006) Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy. J Nucl Med 47:6-13
43. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220
44. Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23(11):2477-2492
45. Ma CX, Adjei AA, Salavaggione OE et al (2005) Human aromatase: Gene resequencing and functional genomics. Cancer Res 65:11071-11082
46. Martin LA, Farmer I, Johnston SR et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278:30458-30468
47. Nicholson RI, Staka C, Boyns F et al (2004) Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: New opportunities for therapy. Endocr Relat Cancer 11:623-641
48. Santen RJ, Song RX, Zhang Z et al (2003) Adaptive hypersensitivity to estrogen: Mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 10:111-130
49. Li T, Christos P, Sparano JA et al (2007) Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor positive breast cancer: New York Cancer Consortium Trial P6205. J Clin Oncol 25[Suppl]:1037
50. Lebowitz PF, Eng-Wong J, Widemann BC et al (2005) A phase I trial and pharmacokinetic study of tipifarnib a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin Cancer Res 11:1247-1252
51. Chow C, Sun I, Jassem J et al (2006) Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastasic breast cancer. In the San Antonio Breast Cancer Symposium. In the san Antonio should read: Br Can Res Treat 2006, Dec. S286. Abstract 6091
52. Traina TA, Rugo H, Caravelli J, et al (2006) Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). No 18S (June 20 Supplement) 24:3050
53. Johnston et al (2007) A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. Sep 13; [Epub ahead of print] PMID: 17851757 [Pub Med - as supplied by publisher]
54. Smith IE, Walsh G, Skene A et al (2007) A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816-3822
55. Polychronis A, Sinnett HD, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391
56. Marcom PK, Isaacs C, Harris L et al (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49
57. Kaufman B, Mackey J, Clemens M, et al (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). Paper presented at: 31st Annual Congress of the European Society for Clinical Oncology; September 29-October 3, 2006; Istanbul, Turkey. Abstract LBA2. Available at: http://annonc.oxfordjournals.org. Accessed: December 12
58. Ge H, Walhout AJ, Vidal M (2003) Integrating 'omic' information: A bridge between genomics and systems biology. Trends Genet 19:551-560
59. Liu ET (2005) Systems biology, integrative biology, predictive biology. Cell 121:505-506